HIV Drugs Market Size

Global HIV Drugs Market Overview

The Human Immunodeficiency Virus (HIV) Drugs Market Size was valued at USD 22.5 billion in 2022. The Human Immunodeficiency Virus drugs industry is projected to grow from USD 23.37 Billion in 2023 to USD 31.74 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.90% during the forecast period (2023 - 2032). The growth in patients number for HIV and its treatment are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

HIV Drugs Market Trends

• Growing prevalence of HIV/AIDS is driving the market growth

Market CAGR for human immunodeficiency virus (HIV) drugs is being driven by the rising number of HIV/AIDS. The World Health Organisation (WHO) estimates that 33.0 million individuals worldwide are HIV-positive and that 1.7 million new cases of HIV infection were recorded in 2019. Joint United Nations Programme on HIV/AIDS estimates that in 2019, 2.2 million people were living with HIV in Western and Central Europe and North America, 20.7 million in Eastern and Southern Africa, 5.8 million in the Asia Pacific, and an additional 4.9 million people living with HIV in the rest of Western and Central Africa. Antiretroviral (ARV) medications are in high demand due to the enormous patient population spread over several areas. This is predicted to fuel the market for HIV/AIDS medications.

The creation of antiretroviral treatment as a long-acting suppression (ATLAS) and the first long-acting injectable formulation are two trends in the worldwide market. As a result of a significant number of patients now having access to the once-monthly dose, the new ATLAS regimens are a practical treatment choice, and doctors believe that compliance rates will rise as a result. The new comprehensive long-acting regimen, which combines cabotegravir and rilpivirine, can be used as an alternative to the already available HIV medications. In comparison to the HIV medications that are most frequently administered, the new injectable formulation has now made it onto the world market and raised the bar for healthcare. This new therapy reduces dosage days from 365 to 12 per year. The new medication contains the ViiV Healthcare product Cabenuva (cabotegravir, rilpivirine). The Cabenuva medication was given FDA approval in January 2020. During the anticipated time, the market's expansion will be diversified by these future new trends.

The importance of research and development (R&D) in the area of anti-human immunodeficiency virus (HIV) medications is expected to increase, which will lead to a rise in drug developments worldwide. Numerous reputable businesses are participating in various investment activities to compete in the industry, including ViiV Healthcare, Boehringer Ingelheim International GmbH, and Gilead Sciences. Other market participants are participating in joint ventures and introducing new products. Numerous medication advancements have recently resulted from the increased focus on HIV drug research and development (R&D). Gilead Sciences, ViiV Healthcare, and Boehringer Ingelheim International GmbH are three significant corporations in these investment projects. Additionally, many businesses participate in international drug launches and strategic alliances. Thus, driving the Human Immunodeficiency Virus (HIV) Drugs market revenue.

HIV Drugs Market Segment Insights

HIV Drugs Type Insights

The Human Immunodeficiency Virus Drugs Market segmentation, based on type, includes nucleoside, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, and ccr5 antagonists. The nucleoside segment dominated the market, accounting for 45% of market revenue. This dominance is attributable to the rising demand for this medicine class due to improved outcomes in treating co-infections and HIV. This pharmacological class also includes the most progress. Due to improving outcomes in the pharmacological treatment of HIV and co-infections, this pharmaceutical class is increasingly in demand, which accounts for its dominance.

HIV Drugs End User Insights

The Human Immunodeficiency Virus Drugs market segmentation, based on End User, includes hospitals & clinics, and specialty centers. The hospitals & clinics category generated the most income (70.4%). Due to increased patients seeking HIV treatment in hospitals, the hospital pharmacies category is anticipated to have the biggest market share over the projection period. Furthermore, the segmental growth would be supported by hospital pharmacies' rising prescription antiretroviral drug sales for the treatment of HIV.

Figure 1: Human Immunodeficiency Virus Drugs Market, by End User, 2022 & 2032 (USD billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

HIV Drugs Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Human Immunodeficiency Virus (HIV) Drugs market area will dominate this market; the rising incidence of HIV infection among Americans is to blame for this region's dominance. The Centres for Disease Control (CDC) estimated in 2021 that at the end of 2018, around 1.2 million people were living with HIV. Such a large patient group greatly increases the need for HIV medications. The population's awareness is another element influencing the progress of the region. Additionally, the existence of major players who provide cutting-edge HIV medications to treat HIV infection would further accelerate market growth.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Human Immunodeficiency Virus Drugs Market Share By Region 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Human Immunodeficiency Virus Drugs market accounts for the second-largest market share due to the rise in HIV infection rates and the concentration of HIV medicine manufacturers in this area. Additionally, the growing strategic partnerships between European businesses will increase drug availability, supporting expanding the market in this area. Further, the German Human Immunodeficiency Virus (HIV) Drugs market held the largest market share. The UK Human Immunodeficiency Virus (HIV) Drugs market was the fastest-growing market in the European region.

The Asia-Pacific Human Immunodeficiency Virus Drugs Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to the numerous HIV patients in highly populated nations like China and India. In addition, the market is projected to be driven by the rising number of treatment programs and the rising financing from the private sector and healthcare organizations. Moreover, China's Human Immunodeficiency Virus (HIV) Drugs market held the largest market share. The Indian Human Immunodeficiency Virus Drugs market was the fastest-growing market in the Asia-Pacific region.

Human Immunodeficiency Virus (HIV) Drugs market Players & Competitive Insights

Leading market players are making significant R&D investments to diversify their product offerings, which would drive the market for Human Immunodeficiency Virus (HIV) Drugs to increase in size. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The Human Immunodeficiency Virus (HIV) Drugs industry must provide affordable products to grow and thrive in an increasingly competitive and challenging market environment.

One of the primary business strategies manufacturers employ in the worldwide Human Immunodeficiency Virus (HIV) Drugs industry to assist customers and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the Human Immunodeficiency Virus (HIV) Drugs industry has offered some of the most significant advantages to medicine. Major players in the Human Immunodeficiency Virus (HIV) Drugs market, including Bristol-Myers Squibb Company, Theratechnologies Inc. and others, are attempting to increase market demand by investing in research and development operations.

Located in Foster City, California, Gilead Sciences, Inc. (/lid/) is an American biopharmaceutical company that specializes in researching and creating antiviral medications used to treat COVID-19, hepatitis B, hepatitis C, influenza, and HIV/AIDS. These medications include ledipasvir/sofosbuvir and sofosbuvir. Gilead is a component of the S&P 500 and the NASDAQ Biotechnology Index. In December 2020, gilead sciences, inc., announced a grant of USD 1.4 million for its 'Gilead Asia pacific rainbow award program' in the region. The program is a component of Gilead's effort to strengthen public-private partnerships in the Asia Pacific region to address issues encountered by patients who are infected with HIV.

More than 150 individuals are employed by Theratechnologies, created in 1993 and operated in Canada, the US, and Europe. Theratechnologies, headquartered in Montreal, Quebec (Canada), commercializes two HIV medications and researches HIV, NASH, and oncology. In July 2020, Theratechnologies Europe Limited, a branch of Theratechnologies Inc. in Europe, worked with Loxxess to distribute the antiviral medication Trogarzo throughout the continent.

Key Companies in the Human Immunodeficiency Virus Drugs market include

• Boehringer Ingelheim International GmbH (Germany)


• Cipla Inc. (India)


• Merck & Co., Inc. (US)


• AbbVie Inc. (US)


• Bristol-Myers Squibb Company (US)


• Teva Pharmaceutical Industries Ltd (Israel)


• Hoffmann-La Roche Ltd (Switzerland)


• Pfizer Inc. (US)


• Aurobindo Pharma (India)


• Celltrion Healthcare Co., Ltd (South Korea)


• ViiV Healthcare (UK)


• Gilead Sciences, Inc. (US)

HIV Drugs Industry Developments

July 2021:To make darunavir paired with ritonavir (DRV/r) as a second-line medication for HIV patients living in low and medium-income countries, Unitaid and Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with pharmaceutical company Hetero Labs LTD. The price of the deal is US$ 210 per patient/year.

March 2021:An agreement for collaboration to co-develop and co-commercialize long-acting HIV medication was made public by Gilead Sciences Inc. and Merck. To create a two-drug HIV treatment regimen, the firms want to combine lenacapavir, an experimental capsid inhibitor from Gilead, with islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor from Merck.

HIV Drugs Market Segmentation

HIV Drugs Type Outlook

• 
  

   Nucleoside

  
  


• 
  

  Non-Nucleoside Reverse Transcriptase Inhibitors

  
  


• 
  

  Protease Inhibitors

  
  


• 
  

  Integrase Inhibitors

  
  


• 
  

  Fusion Inhibitors

  
  


• 
  

  CCR5 Antagonist

  
  

HIV Drugs End User Outlook

• 
  

  Hospitals & Clinics

  
  


• 
  

  Specialty Centers

  
  

HIV Drugs Regional Outlook

• 
  

  North America

  
  

• 
  
  
  
  • 
    

    US

    
    
  
  
  • 
    

    Canada

    
    
  
  
  
  

• 
  

  Europe

  
  

• 
  
  
  
  • 
    

    Germany

    
    
  
  
  • 
    

    France

    
    
  
  
  • 
    

    UK

    
    
  
  
  • 
    

    Italy

    
    
  
  
  • 
    

    Spain

    
    
  
  
  • 
    

    Rest of Europe

    
    
  
  
  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America